{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T14:12:25Z","timestamp":1779372745897,"version":"3.53.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04923-2","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T11:55:20Z","timestamp":1764244520000},"page":"1925-1939","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of androgen deprivation therapy and androgen receptor pathway inhibitors on cardiac structure and function evaluated by echocardiography in males with prostate cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0818-1180","authenticated-orcid":false,"given":"Bj\u00f8rn R\u00f8rb\u00e6k","family":"Kemp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9221-8944","authenticated-orcid":false,"given":"Emil","family":"Durukan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-7511","authenticated-orcid":false,"given":"Kristoffer Grundtvig","family":"Skaarup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4762-039X","authenticated-orcid":false,"given":"Peter Busch","family":"\u00d8stergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"S\u00f8nksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8963-4581","authenticated-orcid":false,"given":"Mikkel","family":"Fode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"4923_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","volume":"43","author":"C Huggins","year":"1941","unstructured":"Huggins C, Stevens R, Hodges CV (1941) Studies on prostatic cancer. Arch Surg 43:209. https:\/\/doi.org\/10.1001\/archsurg.1941.01210140043004","journal-title":"Arch Surg"},{"issue":"24","key":"4923_CR2","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","volume":"360","author":"M Bolla","year":"2009","unstructured":"Bolla M, de Reijke TM, Van Tienhoven G, den Van Bergh ACM, Oddens J, Poortmans PMP, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Pi\u00e9rart M, Mauer ME, Collette L (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516\u20132527. https:\/\/doi.org\/10.1056\/NEJMoa0810095","journal-title":"N Engl J Med"},{"issue":"13","key":"4923_CR3","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fl\u00e9chon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS (2012) Increased survival with Enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197. https:\/\/doi.org\/10.1056\/NEJMoa1207506","journal-title":"N Engl J Med"},{"issue":"21","key":"4923_CR4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fl\u00e9chon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995\u20132005. https:\/\/doi.org\/10.1056\/NEJMoa1014618","journal-title":"N Engl J Med"},{"key":"4923_CR5","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","volume":"26","author":"EM Horwitz","year":"2008","unstructured":"Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU (2008) Ten-year follow-up of radiation therapy oncology group protocol 92\u201302: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26:2497\u20132504. https:\/\/doi.org\/10.1200\/JCO.2007.14.9021","journal-title":"J Clin Oncol"},{"key":"4923_CR6","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","volume":"61","author":"MV Pilepich","year":"2005","unstructured":"Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2014long-term results of phase III RTOG 85\u201331. Int J Radiat Oncol Biol Phys 61:1285\u20131290. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.08.047","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4923_CR7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","volume":"26","author":"M Roach","year":"2008","unstructured":"Roach M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV (2008) Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26:585\u2013591. https:\/\/doi.org\/10.1200\/JCO.2007.13.9881","journal-title":"J Clin Oncol"},{"key":"4923_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","volume":"360","author":"M Bolla","year":"2002","unstructured":"Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Torecilla JL, Pfeffer JR, Cutajar CL, Zurlo A, Pierart M (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103\u2013108. https:\/\/doi.org\/10.1016\/S0140-6736(02)09408-4","journal-title":"Lancet"},{"key":"4923_CR9","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1200\/JCO.20.00315","volume":"38","author":"JA Eastham","year":"2020","unstructured":"Eastham JA, Heller G, Halabi S, Monk JP, Beltran H, Gleave M, Evans CP, Clinton SK, Szmulewitz RZ, Coleman J, Hillman DW, Watt CR, George S, Sanda MG, Hahn OM, Taplin M-E, Parsons JK, Mohler JL, Small EJ, Morris MJ (2020) Cancer and leukemia group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer. J Clin Oncol 38:3042\u20133050. https:\/\/doi.org\/10.1200\/JCO.20.00315","journal-title":"J Clin Oncol"},{"key":"4923_CR10","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","volume":"382","author":"ND Shore","year":"2020","unstructured":"Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B (2020) Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 382:2187\u20132196. https:\/\/doi.org\/10.1056\/NEJMoa2004325","journal-title":"N Engl J Med"},{"key":"4923_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.clgc.2014.07.009","volume":"12","author":"S Edelman","year":"2014","unstructured":"Edelman S, Butler J, Hershatter BW, Khan MK (2014) The effects of androgen deprivation therapy on cardiac function and heart failure: implications for management of prostate cancer. Clin Genitourin Cancer 12:399\u2013407. https:\/\/doi.org\/10.1016\/j.clgc.2014.07.009","journal-title":"Clin Genitourin Cancer"},{"key":"4923_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.119.313046","author":"J-R Hu","year":"2020","unstructured":"Hu J-R, Duncan MS, Morgans AK, Brown JD, Meijers WC, Freiberg MS, Salem J-E, Beckman JA, Moslehi JJ (2020) Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. Arterioscler Thromb Vasc Biol. https:\/\/doi.org\/10.1161\/ATVBAHA.119.313046","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4923_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.08.031","author":"MK Aziz","year":"2024","unstructured":"Aziz MK, Molony D, Monlezun D, Holder T, Brunckhorst O, Higgason N, Roland J, Magill R, Fatakdawala M, Iacobucci A, Mody-Bailey N, Owen C, Zarker A, Thames E, Swaby J, Xiao D, Choi L, Desai S, Galan J, Deng B, Hartshorne T, Nichols A, Zhang A, Imber J, Song J, Jones W, Rivas A, Sanchez D, Guhan M, Gandaglia G, Ranganath S, Jacob J, Howell S, Plana J, van den Bergh R, Roberts M, Sommer SG, Oldenburg J, Ploussard G, Tilki D, Schoots I, Briers E, Stranne J, Rouviere O, van Oort I, Oprea-Lager D, De Santis M, Cornford P, Koutroumpakis E, Ziaolhagh A, Ali A, Wamique Yusuf S, Iliescu C, Canfield S (2024) Prostate cancer therapy cardiotoxicity map (PROXMAP) for advanced disease states: a systematic review and network meta-analysis with Bayesian modeling of treatment histories. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2024.08.031","journal-title":"Eur Urol"},{"key":"4923_CR14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26209","author":"M Kakarla","year":"2022","unstructured":"Kakarla M, Ausaja Gambo M, Yousri Salama M, Haidar Ismail N, Tavalla P, Uppal P, Mohammed SA, Rajashekar S, Giri Ravindran S, Hamid P (2022) Cardiovascular effects of androgen deprivation therapy in prostate cancer patients: a systematic review. Cureus. https:\/\/doi.org\/10.7759\/cureus.26209","journal-title":"Cureus"},{"key":"4923_CR15","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1093\/jnci\/djs299","volume":"104","author":"MM Epstein","year":"2012","unstructured":"Epstein MM, Edgren G, Rider JR, Mucci LA, Adami H-O (2012) Temporal trends in cause of death among Swedish and US men with prostate cancer. JNCI J Natl Cancer Inst 104:1335\u20131342. https:\/\/doi.org\/10.1093\/jnci\/djs299","journal-title":"JNCI J Natl Cancer Inst"},{"key":"4923_CR16","unstructured":"Yang L, Lin H, Xie S, Wan J, Ao J, Zhang W (2022) Dilated cardiomyopathy induced by bicalutamide. Chin J Pharma Covigil"},{"key":"4923_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1536\/ihj.18-127","volume":"60","author":"K Hasegawa","year":"2019","unstructured":"Hasegawa K, Morishita T, Miyanaga D, Hisazaki K, Kaseno K, Miyazaki S, Uzui H, Ohno S, Horie M, Tada H (2019) Medical castration is a rare but possible trigger of torsade de pointes and ventricular fibrillation. Int Heart J 60:193\u2013198. https:\/\/doi.org\/10.1536\/ihj.18-127","journal-title":"Int Heart J"},{"key":"4923_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-023-00160-7","volume":"9","author":"A Kumar","year":"2023","unstructured":"Kumar A, Reddy A, Sekar A (2023) Enzalutamide induced non-ischemic cardiomyopathy. A case report and review of literature on anti-androgen therapy-related cardiovascular events. Cardio-Oncol 9:9. https:\/\/doi.org\/10.1186\/s40959-023-00160-7","journal-title":"Cardio-Oncol"},{"key":"4923_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s10396-018-0897-7","volume":"46","author":"T Tsugu","year":"2019","unstructured":"Tsugu T, Nagatomo Y, Nakajima Y, Kageyama T, Akise Y, Endo J, Itabashi Y, Murata M, Mitamura H (2019) Cancer therapeutics-related cardiac dysfunction in a patient treated with abiraterone for castration-resistant prostate cancer. J Med Ultrason 46:239\u2013243. https:\/\/doi.org\/10.1007\/s10396-018-0897-7","journal-title":"J Med Ultrason"},{"key":"4923_CR20","volume":"2","author":"B Freeman","year":"2016","unstructured":"Freeman B, Wang J (2016) Dilated cardiomyopathy after sequential therapy with abiraterone and enzalutamide. Oncol Cancer Case Rep 2:115","journal-title":"Oncol Cancer Case Rep"},{"key":"4923_CR21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.60298","author":"AY Abdulfattah","year":"2024","unstructured":"Abdulfattah AY, Tajuddin S, Akkari N, Elsayed OI, Graham-Hill S (2024) A rare case of bicalutamide-induced severe congestive heart failure in a patient with advanced prostate cancer. Cureus. https:\/\/doi.org\/10.7759\/cureus.60298","journal-title":"Cureus"},{"key":"4923_CR22","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","volume":"24","author":"M Braga-Basaria","year":"2006","unstructured":"Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S (2006) Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24:3979\u20133983. https:\/\/doi.org\/10.1200\/JCO.2006.05.9741","journal-title":"J Clin Oncol"},{"key":"4923_CR23","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/bju.14609","volume":"123","author":"PB \u00d8stergren","year":"2019","unstructured":"\u00d8stergren PB, Kistorp C, Fode M, Bennedb\u00e6k FN, Faber J, S\u00f8nksen J (2019) Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study. BJU Int 123:602\u2013611. https:\/\/doi.org\/10.1111\/bju.14609","journal-title":"BJU Int"},{"key":"4923_CR24","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O\u2019Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448\u20134456. https:\/\/doi.org\/10.1200\/JCO.2006.06.2497","journal-title":"J Clin Oncol"},{"key":"4923_CR25","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.3390\/curroncol28050289","volume":"28","author":"GS Gheorghe","year":"2021","unstructured":"Gheorghe GS, Hodorogea AS, Ciobanu A, Nanea IT, Gheorghe ACD (2021) Androgen deprivation therapy, hypogonadism and cardiovascular toxicity in men with advanced prostate cancer. Curr Oncol 28:3331\u20133346. https:\/\/doi.org\/10.3390\/curroncol28050289","journal-title":"Curr Oncol"},{"key":"4923_CR26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1161\/01.CIR.98.3.256","volume":"98","author":"JD Marsh","year":"1998","unstructured":"Marsh JD, Lehmann MH, Ritchie RH, Gwathmey JK, Green GE, Schiebinger RJ (1998) Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation 98:256\u2013261. https:\/\/doi.org\/10.1161\/01.CIR.98.3.256","journal-title":"Circulation"},{"key":"4923_CR27","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac132","author":"E Svedlund Eriksson","year":"2022","unstructured":"Svedlund Eriksson E, Johansson I, M\u00e5rtensson AKF, Lantero Rodriguez M, Schilperoort M, Kroon J, Kooijman S, Omerovic E, Andersson L, Levin MC, Rensen PCN, Tivesten \u00c5 (2022) Castration of male mice induces metabolic remodeling of the heart. J Endocr Soc. https:\/\/doi.org\/10.1210\/jendso\/bvac132","journal-title":"J Endocr Soc"},{"key":"4923_CR28","doi-asserted-by":"publisher","first-page":"E449","DOI":"10.1152\/ajpendo.00054.2003","volume":"285","author":"KL Golden","year":"2003","unstructured":"Golden KL, Marsh JD, Jiang Y, Brown T, Moulden J (2003) Gonadectomy of adult male rats reduces contractility of isolated cardiac myocytes. Am J Physiol Endocrinol Metab 285:E449\u2013E453. https:\/\/doi.org\/10.1152\/ajpendo.00054.2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4923_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1385\/ENDO:24:2:137","volume":"24","author":"KL Golden","year":"2004","unstructured":"Golden KL, Marsh JD, Jiang Y, Moulden J (2004) Gonadectomy alters myosin heavy chain composition in isolated cardiac myocytes. Endocrine 24:137\u2013140. https:\/\/doi.org\/10.1385\/ENDO:24:2:137","journal-title":"Endocrine"},{"key":"4923_CR30","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. The BMJ 372","DOI":"10.1136\/bmj.n71"},{"key":"4923_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"4923_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4236\/wjcd.2017.79029","volume":"07","author":"JF Schmidt","year":"2017","unstructured":"Schmidt JF, Andersen LJ, Uth J, Hornstrup T, Christensen J, Midtgaard J, Brasso K, Krustrup P, R\u00f8rth M, Hansen PR (2017) Cardiac structure and function in men with prostate cancer receiving androgen-deprivation therapy and the effects of recreational small-sided football training: a randomized controlled trial. World J Cardiovasc Dis 07:308\u2013322. https:\/\/doi.org\/10.4236\/wjcd.2017.79029","journal-title":"World J Cardiovasc Dis"},{"key":"4923_CR33","unstructured":"Wells GA, Wells G, Shea B, Shea B, O\u2019Connell D, Peterson J, Welch, Losos M, Tugwell P, Ga SW, Zello GA, Petersen JA (2014) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses."},{"key":"4923_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"4923_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12874-024-02356-6","volume":"24","author":"A Abbas","year":"2024","unstructured":"Abbas A, Hefnawy MT, Negida A (2024) Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis. BMC Med Res Methodol 24:243. https:\/\/doi.org\/10.1186\/s12874-024-02356-6","journal-title":"BMC Med Res Methodol"},{"key":"4923_CR36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/9781119536604.ch10","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JJ Deeks","year":"2019","unstructured":"Deeks JJ, Higgins JP, Altman DG (2019) Analysing data and undertaking meta-analyses. Cochrane handbook for systematic reviews of interventions. Wiley, pp 241\u2013284"},{"key":"4923_CR37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2217\/fon-2017-0385","volume":"14","author":"V Prati","year":"2018","unstructured":"Prati V, Ruatta F, Aversa C, Gernone A, Galizia D, Bonzano A, Torino S, Nuzzolese I, Marandino L, Aglietta M, Ortega C (2018) Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation. Future Oncol 14:443\u2013448. https:\/\/doi.org\/10.2217\/fon-2017-0385","journal-title":"Future Oncol"},{"key":"4923_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2265.2007.02999.x","volume":"68","author":"F Dockery","year":"2008","unstructured":"Dockery F, Bulpitt CJ, Agarwal S, Vernon C, Nihoyannopoulos P, Kemp M, Hooper J, Rajkumar C (2008) Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer. Clin Endocrinol (Oxf) 68:59\u201365. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02999.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"4923_CR39","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s11255-019-02184-4","volume":"51","author":"BG Kanar","year":"2019","unstructured":"Kanar BG, Ozben B, Sunbul M, \u015eener E, Ozkan O, T\u0131nay I, Tigen MK (2019) Androgen-deprivation therapy impairs left ventricle functions in prostate cancer patients. Int Urol Nephrol 51:1107\u20131112. https:\/\/doi.org\/10.1007\/s11255-019-02184-4","journal-title":"Int Urol Nephrol"},{"key":"4923_CR40","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/echo.15043","volume":"38","author":"ACD Gheorghe","year":"2021","unstructured":"Gheorghe ACD, Ciobanu A, Hodorogea AS, Radavoi GD, Jinga V, Rascu ASC, Nanea IT, Gheorghe GS (2021) Subclinical left ventricular dysfunction in men under androgen deprivation therapy for prostate cancer, revealed by speckle-tracking-derived parameters, repolarization, and myocardial injury markers. Echocardiography 38:632\u2013640. https:\/\/doi.org\/10.1111\/echo.15043","journal-title":"Echocardiography"},{"key":"4923_CR41","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.echo.2024.03.006","volume":"37","author":"TW Churchill","year":"2024","unstructured":"Churchill TW, Smith MR, Michaelson MD, Lee RJ, Guseh JS, Wasfy MM, Meneely E, Olivier K, Baggish AL, Saylor PJ (2024) Cardiac structural changes and declining cardiorespiratory fitness during androgen deprivation therapy for prostate cancer. J Am Soc Echocardiogr 37:706\u2013708. https:\/\/doi.org\/10.1016\/j.echo.2024.03.006","journal-title":"J Am Soc Echocardiogr"},{"key":"4923_CR42","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030447","author":"D Chen","year":"2023","unstructured":"Chen D, Lee C, Tsai M, Hsieh M, Chuang C, Pang S, Chen S, Tseng C, Chang S, Chu P, Hsieh I, Wu VC, Huang W (2023) Cancer therapy-related cardiac dysfunction in patients with prostate cancer undergoing androgen deprivation therapy. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.123.030447","journal-title":"J Am Heart Assoc"},{"key":"4923_CR43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/ejechocard\/jer021","volume":"12","author":"V Mor-Avi","year":"2011","unstructured":"Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G, Galderisi M, Marwick T, Nagueh SF, Sengupta PP, Sicari R, Smiseth OA, Smulevitz B, Takeuchi M, Thomas JD, Vannan M, Voigt J-U, Zamorano JL (2011) Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE\/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. Eur J Echocardiogr 12:167\u2013205. https:\/\/doi.org\/10.1093\/ejechocard\/jer021","journal-title":"Eur J Echocardiogr"},{"key":"4923_CR44","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/bjc.2017.280","volume":"117","author":"R Haque","year":"2017","unstructured":"Haque R, UlcickasYood M, Xu X, Cassidy-Bushrow AE, Tsai H-T, Keating NL, Van Den Eeden SK, Potosky AL (2017) Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. Br J Cancer 117:1233\u20131240. https:\/\/doi.org\/10.1038\/bjc.2017.280","journal-title":"Br J Cancer"},{"key":"4923_CR45","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/jcph.1332","volume":"59","author":"H Kao","year":"2019","unstructured":"Kao H, Kao L, Li I, Pan K, Shih J, Chou Y, Wu S (2019) Androgen deprivation therapy use increases the risk of heart failure in patients with prostate cancer: a population-based cohort study. J Clin Pharmacol 59:335\u2013343. https:\/\/doi.org\/10.1002\/jcph.1332","journal-title":"J Clin Pharmacol"},{"key":"4923_CR46","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/ehjci\/jex244","volume":"18","author":"M Galderisi","year":"2017","unstructured":"Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, Donal E, Sade LE, Ernande L, Garbi M, Grapsa J, Hagendorff A, Kamp O, Magne J, Santoro C, Stefanidis A, Lancellotti P, Popescu B, Habib G, Flachskampf FA, Gerber B, Gimelli A, Haugaa K (2017) Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 18:1301\u20131310. https:\/\/doi.org\/10.1093\/ehjci\/jex244","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"4923_CR47","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, de Boer RA, Christian Schulze P, Abdelhamid M, Aboyans V, Adamopoulos S, Anker SD, Arbelo E, Asteggiano R, Bauersachs J, Bayes-Genis A, Borger MA, Budts W, Cikes M, Damman K, Delgado V, Dendale P, Dilaveris P, Drexel H, Ezekowitz J, Falk V, Fauchier L, Filippatos G, Fraser A, Frey N, Gale CP, Gustafsson F, Harris J, Iung B, Janssens S, Jessup M, Konradi A, Kotecha D, Lambrinou E, Lancellotti P, Landmesser U, Leclercq C, Lewis BS, Leyva F, Linhart A, L\u00f8chen M-L, Lund LH, Mancini D, Masip J, Milicic D, Mueller C, Nef H, Nielsen J-C, Neubeck L, Noutsias M, Petersen SE, Sonia Petronio A, Ponikowski P, Prescott E, Rakisheva A, Richter DJ, Schlyakhto E, Seferovic P, Senni M, Sitges M, Sousa-Uva M, Tocchetti CG, Touyz RM, Tschoepe C, Waltenberger J, Adamo M, Baumbach A, B\u00f6hm M, Burri H, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gardner RS, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"4923_CR48","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.cjca.2016.05.001","volume":"32","author":"TH Marwick","year":"2016","unstructured":"Marwick TH (2016) Cancer therapy-related cardiac dysfunction: unresolved issues. Can J Cardiol 32:842\u2013846. https:\/\/doi.org\/10.1016\/j.cjca.2016.05.001","journal-title":"Can J Cardiol"},{"key":"4923_CR49","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1210\/jc.2005-2507","volume":"91","author":"MR Smith","year":"2006","unstructured":"Smith MR, Lee H, Nathan DM (2006) Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91:1305\u20131308. https:\/\/doi.org\/10.1210\/jc.2005-2507","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"4923_CR50","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","volume":"28","author":"M Van Hemelrijck","year":"2010","unstructured":"Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, Lambe M, Stattin P, Adolfsson J (2010) Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol 28(21):3448\u20133456. https:\/\/doi.org\/10.1200\/JCO.2010.29.1567","journal-title":"J Clin Oncol"},{"key":"4923_CR51","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","volume":"202","author":"D Margel","year":"2019","unstructured":"Margel D, Peer A, Ber Y, Shavit-Grievink L, Tabachnik T, Sela S, Witberg G, Baniel J, Kedar D, Duivenvoorden WCM, Rosenbaum E, Pinthus JH (2019) Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J Urol 202:1199\u20131208. https:\/\/doi.org\/10.1097\/JU.0000000000000384","journal-title":"J Urol"},{"key":"4923_CR52","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000503906","volume":"104","author":"R Liu","year":"2020","unstructured":"Liu R, Zhou J, Xia S, Li T (2020) Androgen deprivation therapy and the risk of stroke in patients with prostate cancer: an updated systematic review and meta-analysis. Urol Int 104:214\u2013221. https:\/\/doi.org\/10.1159\/000503906","journal-title":"Urol Int"},{"key":"4923_CR53","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","volume":"65","author":"PC Albertsen","year":"2014","unstructured":"Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J (2014) Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65:565\u2013573. https:\/\/doi.org\/10.1016\/j.eururo.2013.10.032","journal-title":"Eur Urol"},{"key":"4923_CR54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11864-021-00846-z","volume":"22","author":"AA Challa","year":"2021","unstructured":"Challa AA, Calaway AC, Cullen J, Garcia J, Desai N, Weintraub NL, Deswal A, Kutty S, Vallakati A, Addison D, Baliga R, Campbell CM, Guha A (2021) Cardiovascular toxicities of androgen deprivation therapy. Curr Treat Options Oncol 22:47. https:\/\/doi.org\/10.1007\/s11864-021-00846-z","journal-title":"Curr Treat Options Oncol"},{"key":"4923_CR55","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00392-019-01508-9","volume":"109","author":"M Laufer-Perl","year":"2020","unstructured":"Laufer-Perl M, Arnold JH, Mor L, Amrami N, Derakhshesh M, Moshkovits Y, Sadeh B, Arbel Y, Topilsky Y, Rozenbaum Z (2020) The association of reduced global longitudinal strain with cancer therapy-related cardiac dysfunction among patients receiving cancer therapy. Clin Res Cardiol 109:255\u2013262. https:\/\/doi.org\/10.1007\/s00392-019-01508-9","journal-title":"Clin Res Cardiol"},{"key":"4923_CR56","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1161\/CIRCULATIONAHA.118.038772","volume":"139","author":"X Jia","year":"2019","unstructured":"Jia X, Sun W, Hoogeveen RC, Nambi V, Matsushita K, Folsom AR, Heiss G, Couper DJ, Solomon SD, Boerwinkle E, Shah A, Selvin E, de Lemos JA, Ballantyne CM (2019) High-sensitivity troponin I and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study. Circulation 139:2642\u20132653. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038772","journal-title":"Circulation"},{"key":"4923_CR57","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2217\/bmm-2019-0158","volume":"13","author":"FS Davidovski","year":"2019","unstructured":"Davidovski FS, Goetze JP (2019) Proanp and Probnp in plasma as biomarkers of heart failure. Biomark Med 13:1129\u20131135. https:\/\/doi.org\/10.2217\/bmm-2019-0158","journal-title":"Biomark Med"},{"key":"4923_CR58","doi-asserted-by":"publisher","DOI":"10.1177\/1758834017745819","volume":"10","author":"A Cavo","year":"2018","unstructured":"Cavo A, Rubagotti A, Zanardi E, Fabbroni C, Zinoli L, Di Meglio A, Arboscello E, Bellodi A, Spallarossa P, Cattrini C, Messina C, Boccardo F (2018) Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. Ther Adv Med Oncol 10:1758834017745819. https:\/\/doi.org\/10.1177\/1758834017745819","journal-title":"Ther Adv Med Oncol"},{"key":"4923_CR59","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.tranon.2016.08.001","volume":"9","author":"S Campora","year":"2016","unstructured":"Campora S, Campazzi E, Zanardi S, Puntoni M, Piccininno M, Piccardo A, Shoushtari Zadeh Naseri M, Defferrari C, Provinciali N, Petrera M, Marra D, Biscaldi E, Antonucci GC, Ricci D, Clavarezza M, Gennari A, Gozza A, D\u2019Amico M, Mori M, DeCensi A (2016) Association of biomarkers with serious cardiac adverse events during Abiraterone acetate treatment in castration resistant prostate cancer. Transl Oncol 9:600\u2013605. https:\/\/doi.org\/10.1016\/j.tranon.2016.08.001","journal-title":"Transl Oncol"},{"key":"4923_CR60","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/1758834016656493","volume":"8","author":"E Verzoni","year":"2016","unstructured":"Verzoni E, Grassi P, Ratta R, Niger M, De Braud F, Valdagni R, Procopio G (2016) Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. Ther Adv Med Oncol 8:323\u2013330. https:\/\/doi.org\/10.1177\/1758834016656493","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"4923_CR61","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/COC.0b013e3182a790ce","volume":"38","author":"G Procopio","year":"2015","unstructured":"Procopio G, Grassi P, Testa I, Verzoni E, Torri V, Salvioni R, Valdagni R, de Braud F (2015) Safety of Abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors. Am J Clin Oncol 38(5):479\u2013482. https:\/\/doi.org\/10.1097\/COC.0b013e3182a790ce","journal-title":"Am J Clin Oncol"},{"key":"4923_CR62","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.tps244","volume":"28","author":"G Gibney","year":"2010","unstructured":"Gibney G, Elfiky A, Hoimes CJ, Burns A, Rowen E, McDonough JA, Lampert R, Gross C, Kelly WK (2010) Assessing cardiac risk using heart rate variability in a phase II study of androgen-deprivation therapy and bevacizumab in noncastrate metastatic prostate cancer patients. J Clin Oncol 28:TPS244\u2013TPS244. https:\/\/doi.org\/10.1200\/jco.2010.28.15_suppl.tps244","journal-title":"J Clin Oncol"},{"issue":"10_Supplement","key":"4923_CR63","doi-asserted-by":"publisher","first-page":"A887-65","DOI":"10.1016\/S0735-1097(15)60887-7","volume":"65","author":"Z Ali","year":"2015","unstructured":"Ali Z, Greer DM, Shearer R, Alemu A, Jahangir A (2015) Androgen suppression effects on heart failure in patients with prostate cancer. J Am Coll Cardiol 65(10_Supplement):A887-65-A887. https:\/\/doi.org\/10.1016\/S0735-1097(15)60887-7","journal-title":"J Am Coll Cardiol"},{"key":"4923_CR64","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1249\/01.mss.0001062160.82772.15","volume":"56","author":"A Bigaran","year":"2024","unstructured":"Bigaran A, Zopf EM, Trevaskis M, Ischia J, Murphy D, Millar J, La Gerche A, Costello B, Baker MK, Cormie P, Howden E (2024) Impact of exercise on cardiac remodelling in men with prostate cancer undergoing androgen deprivation therapy. Med Sci Sports Exerc 56:1111\u20131112. https:\/\/doi.org\/10.1249\/01.mss.0001062160.82772.15","journal-title":"Med Sci Sports Exerc"},{"key":"4923_CR65","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1002\/cncr.30224","volume":"122","author":"KA Kovtun","year":"2016","unstructured":"Kovtun KA, Chen M, Braccioforte MH, Moran BJ, D\u2019Amico AV (2016) Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer. Cancer 122:3608\u20133614. https:\/\/doi.org\/10.1002\/cncr.30224","journal-title":"Cancer"},{"issue":"41","key":"4923_CR66","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH, Lancellotti P, Thuny F, Abdelhamid M, Aboyans V, Aleman B, Alexandre J, Barac A, Borger MA, Casado-Arroyo R, Cautela J, \u010celutkien\u0117 J, Cikes M, Cohen-Solal A, Dhiman K, Ederhy S, Edvardsen T, Fauchier L, Fradley M, Grapsa J, Halvorsen S, Heuser M, Humbert M, Jaarsma T, Kahan T, Konradi A, Koskinas KC, Kotecha D, Ky B, Landmesser U, Lewis BS, Linhart A, Lip GYH, L\u00f8chen M-L, Malaczynska-Rajpold K, Metra M, Mindham R, Moonen M, Neilan TG, Nielsen JC, Petronio A-S, Prescott E, Rakisheva A, Salem J-E, Savarese G, Sitges M, Berg J, Touyz RM, Tycinska A, Wilhelm M, Zamorano JL, Laredj N, Zelveian P, Rainer PP, Samadov F, Andrushchuk U, Gerber BL, Selimovi\u0107 M, Kinova E, Samardzic J, Economides E, Pudil R, Nielsen KM, Kafafy TA, Vettus R, Tuohinen S, Ederhy S, Pagava Z, Rassaf T, Briasoulis A, Czuriga D, Andersen KK, Smyth Y, Iakobishvili Z, Parrini I, Rakisheva A, Pruthi EP, Mirrakhimov E, Kalejs O, Skouri H, Benlamin H, \u017daliaduonyt\u0117 D, Iovino A, Moore AM, Bursacovschi D, Benyass A, Manintveld O, Bosevski M, Gulati G, Leszek P, Fiuza M, Jurcut R, Vasyuk Y, Foscoli M, Simic D, Slanina M, Lipar L, Martin-Garcia A, H\u00fcbbert L, Kurmann R, Alayed A, Abid L, Zorkun C, Nesukay E, Manisty C, Srojidinova N, Baigent C, Abdelhamid M, Aboyans V, Antoniou S, Arbelo E, Asteggiano R, Baumbach A, Borger MA, \u010celutkien\u0117 J, Cikes M, Collet J-P, Falk V, Fauchier L, Gale CP, Halvorsen S, Iung B, Jaarsma T, Konradi A, Koskinas KC, Kotecha D, Landmesser U, Lewis BS, Linhart A, L\u00f8chen M-L, Mindham R, Nielsen JC, Petersen SE, Prescott E, Rakisheva A, Sitges M, Touyz RM (2022) 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"key":"4923_CR67","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","volume":"121","author":"GN Levine","year":"2010","unstructured":"Levine GN, D\u2019Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk. Circulation 121:833\u2013840. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.192695","journal-title":"Circulation"},{"key":"4923_CR68","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","volume":"133","author":"N Bhatia","year":"2016","unstructured":"Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J (2016) Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer. Circulation 133:537\u2013541. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.012519","journal-title":"Circulation"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04923-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04923-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04923-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:41:23Z","timestamp":1779370883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04923-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":68,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4923"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04923-2","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KGS served on an advisory board for Sanofi; received financial support for congress participation from AstraZeneca outside the submitted work. PB\u00d8 has received honoraria as a speaker and\/or consultant from Astellas Pharma, Ipsen, Merck, Accord Healthcare, Pfizer, Bayer, and Johnson & Johnson. None of the engagements have been related to the submitted work. BRK, ED, JS, and MF have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}